{"url_path":"/sec/hrgn/8-k/2026-06-24/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1563665/0001437749-26-021480-index.html","accession_number":"0001437749-26-021480","cik":"0001563665","ticker":"HRGN","issuer_name":"Harvard Apparatus Regenerative Technology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563665/0001437749-26-021480-index.html","primary_entity_key":"0001563665","primary_entity_name":"Harvard Apparatus Regenerative Technology, Inc."},"word_count":727,"has_tables":true,"body_markdown":"hrgn20260623_8k.htm\n\nfalse\n0001563665\n\n0001563665\n\n2026-06-18\n2026-06-18\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n**FORM ****8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section** **13 or 15(d) of**\n\n**The Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported): June 18, 2026\n\n \n\n \n\n**HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n**001-35853**\n\n**45-5210462**\n\n(State or other jurisdiction\n\nof incorporation)\n\n(Commission File Number)\n\n(IRS Employer Identification No.)\n\n \n\n \n\n**84 October Hill Road, Suite 11****, ****Holliston****, ****MA**\n\n**0****1746**\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\nRegistrant's telephone number, including area code:   **(****774****) ****233-7300**\n\n \n\n \n\n(Former name or former address, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act: None\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\n \n\n \n\n \n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n**Item** **5.07**\n\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 18, 2026, Harvard Apparatus Regenerative Technology, Inc., or the Company, held its Annual Meeting of Stockholders, or the Annual Meeting. At the Annual Meeting, the Company’s stockholders voted on the following proposals: (i) the election of three Director Nominees as Class I Directors, each nominated by the Board of Directors of the Company for a one-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until their earlier resignation or removal, (ii) the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and (iii) the non-binding approval of the compensation of the Company’s named executive officers. The voting results for the matters submitted to a stockholder vote at the Annual Meeting are reported below.\n\n \n\n***Proposal 1 - Election of Directors***\n\n \n\nOn such election of directors proposal, each of Junli (Jerry) He, James Shmerling, and Mao Zhang were elected as Class I Directors, each for a one-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows:\n\n \n\n**Name**\n\n \n\n**Votes** **For**\n\n \n\n**Votes Withheld**\n\n \n\n**Broker Non-Votes**\n\nJunli (Jerry) He\n\n \n\n12,802,162\n\n \n\n859,270\n\n \n\n1,274,478\n\nJames Shmerling\n\n \n\n10,725,274\n\n \n\n2,936,158\n\n \n\n1,274,478\n\nMao Zhang\n\n \n\n12,804,230\n\n \n\n857,202\n\n \n\n1,274,478\n\n \n\n \n\n***Proposal 2***–***Ratification of the appointment of CBIZ CPAs P.C. as the Company***’***s*** ***independent registered public accounting firm for the fiscal year ending December 31, 2026***\n\n \n\nThe ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm was approved as follows:\n\n \n\n**Votes For**\n\n \n\n**Votes Against**\n\n \n\n**Votes Abstained**\n\n \n\n**Broker Non-Votes**\n\n \n\n \n\n14,077,329\n\n \n\n \n\n \n\n5,417\n\n \n\n \n\n \n\n853,164\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n***Proposal 3***–***Approval, by Non-Binding Advisory Vote, of the Compensation of the Company***’***s*** ***Named Executive Officers***\n\n \n\nThe compensation of the Company’s named executive officers was approved, by a non-binding advisory vote, as follows:\n\n \n\n**Votes For**\n\n \n\n**Votes Against**\n\n \n\n**Votes Abstained**\n\n \n\n**Broker Non-Votes**\n\n \n\n \n\n12,467,264\n\n \n\n \n\n \n\n39,284\n\n \n\n \n\n \n\n1,154,884\n\n \n\n \n\n \n\n1,274,478\n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n**HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.** \n\n \n\n \n\n(Registrant)\n\n \n\n \n\n \n\n**June 24, 2026**\n\n \n\n**/s/ ** ** Junli He**\n\n(Date)\n\n \n\nJunli He\n\n \n\n \n\n*Chief Executive Officer*"}